Answers are grounded in this paper and cite their sources.
Background Locally advanced microsatellite stable or mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC) shows heterogeneous responses to neoadjuvant immunotherapy. Host systemic nutritional-inflammatory status and its dynamic changes may affect antitumor immune efficacy. This study aimed to explore their predictive value for neoadjuvant immunotherapy efficacy. Method A total of 342 locally advanced MSS/pMMR CRC patients receiving neoadjuvant PD-1 inhibitor plus CAPOX regimen (capecitabine plus oxaliplatin) were retrospectively enrolled. Patients were divided into treatment-sensitive (TRG 0-1) and treatment-resistant (TRG 2-3) groups, then randomly assigned to training and validation sets at a 7:3 ratio. LASSO and multivariable logistic regression were used to screen independent predictors and construct a nomogram. Model performance was assessed by ROC, calibration curves, decision-curve analysis (DCA), and Bootstrap internal validation. Results The treatment-sensitive group had 105 patients (30.7%). Multivariable analysis identified age (OR = 0.96, 95% CI: 0.93–0.99), post- neoadjuvant treatment LogCEA (OR = 0.23, 95% CI: 0.12–0.44), and a 50-unit increase in the advanced lung cancer inflammation index (ΔALI) during neoadjuvant immunotherapy (OR = 1.296, 95% CI: 1.173–1.433) as independent predictors of efficacy. The model and the nomogram constructed based on the above variables achieved AUCs of 0.82 (95% CI: 0.76–0.87) in the training cohort (n = 240) and 0.73 (95% CI: 0.60–0.82) in the validation cohort (n = 102), with a negative predictive value (NPV) of 0.79 (95% CI: 0.70-0.86) in the validation cohort. The C-index after Bootstrap internal calibration was 0.82 (95% CI: 0.76–0.88), and the calibration curve demonstrated good agreement between predicted probabilities and observed outcomes. DCA confirmed favorable clinical net benefit across a wide range of threshold probabilities. Sensitivity analysis excluding the confounding effect of treatment cycles confirmed the robustness of the model. The final nomogram provided a practical reference tool for individualized prediction of neoadjuvant immunotherapy efficacy. Conclusion Dynamic ΔALI serves as an independent predictor for neoadjuvant immunotherapy efficacy. The nomogram based on nutritional-inflammatory indices exhibits acceptable discrimination and calibration. Given its limited positive predictive performance, it serves as an auxiliary preoperative rule-out tool to identify patients unlikely to derive neoadjuvant immunotherapy benefit and support individualized therapeutic decision-making.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: